Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 20/20 | 0.88 |
| ▸ | BCR | P11274 | 14/20 | 0.88 |
| ▸ | KIT | P10721 | 12/20 | 0.88 |
| ▸ | ABL2 | P42684 | 7/20 | 0.88 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.88 |
| ▸ | LYN | P07948 | 3/20 | 0.88 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.88 |
| ▸ | SRC | P12931 | 2/20 | 0.88 |
| ▸ | SYK | P43405 | 2/20 | 0.88 |
| ▸ | PLK4 | O00444 | 1/20 | 0.88 |
| ▸ | DDX3X | O00571 | 1/20 | 0.88 |
| ▸ | GAK | O14976 | 1/20 | 0.88 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.88 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.88 |
| ▸ | CA12 | O43570 | 1/20 | 0.88 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.88 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.88 |
| ▸ | EGFR | P00533 | 1/20 | 0.88 |
| ▸ | CA1 | P00915 | 1/20 | 0.88 |
| ▸ | CA2 | P00918 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3867268 | 0.97 | ABL1 (0.84) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL3863321 | 0.94 | ABL1 (0.84) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2236091 | 0.94 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL29355523 | 0.94 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL29351601 | 0.94 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3827 | 0.94 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL12034589 | 0.94 | ABL1 (0.78) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL529425 | 0.93 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL1977949 | 0.93 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL16431247 | 0.93 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111329863-A | Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia | 黄泳华 | 2020-06-26 | — | — | CN | claimed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| CN-110559299-A | composition containing pyridyl pyrimidinamine compound and application thereof | 黄泳华 | 2019-12-13 | — | — | CN | claimed |
| CN-110559443-A | composition comprising histamine release-promoting substance and pyridylpyrimidine amine compound, and oral solid preparation containing the same | 黄泳华 | 2019-12-13 | — | — | CN | claimed |
| US-20240240155-A1 | Organoid-Derived Monolayers and Uses Thereof | HUB ORGANOIDS IP B.V. (NL) | 2024-07-18 | — | — | US | disclosed |
| US-20240240155-A1 | Organoid-Derived Monolayers and Uses Thereof | HUB ORGANOIDS IP B.V. (NL) | 2024-07-18 | — | — | US | disclosed |
| US-20230272347-A1 | Differentiation Method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2023-08-31 | — | — | US | disclosed |
| US-20230272347-A1 | Differentiation Method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2023-08-31 | — | — | US | disclosed |
| US-11571475-B1 | Anti-CD70 and BCR-ABL inhibitor combination therapy | UNIVERSITY OF BERN (CH) | 2023-02-07 | — | — | US | disclosed |
| US-20210047618-A1 | Improved Differentiation Method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2021-02-18 | — | — | US | disclosed |
| US-20210040454-A1 | Improved Differentiation Method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2021-02-11 | — | — | US | disclosed |
| CN-111329863-A | Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia | 黄泳华 | 2020-06-26 | — | — | CN | disclosed |
| CN-110559443-A | composition comprising histamine release-promoting substance and pyridylpyrimidine amine compound, and oral solid preparation containing the same | 黄泳华 | 2019-12-13 | — | — | CN | disclosed |
| US-10391168-B1 | Anti-CD70 combination therapy | UNIVERSITY OF BERN (CH) | 2019-08-27 | — | — | US | disclosed |
| US-9907796-B2 | Methods of treating tumoral diseases, or bacterial or viral infections | INHIBIKASE THERAPEUTICS, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170000789-A1 | Methods of Treating Tumoral Diseases, or Bacterial or Viral Infections | SPHAERA PHARMA PTE. LTD. (SG) | 2017-01-05 | — | — | US | disclosed |
| US-9487500-B2 | Compounds and compositions thereof | INHIBIKASE THERAPEUTICS, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20130060030-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE CRYSTALLINE IMATINIB BASE | NATCO PHARMA LIMITED (IN) | 2013-03-07 | — | — | US | disclosed |
| US-20130060030-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE CRYSTALLINE IMATINIB BASE | NATCO PHARMA LIMITED (IN) | 2013-03-07 | — | — | US | disclosed |
| WO-2009060463-A1 | AN ENVIRONMENTALLY FRIENDLY PROCESS FOR THE PREPARATION OF IMATINIB BASE | NATCO PHARMA LIMITED (IN) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272347-A1 | Differentiation Method | MYADM, EPCAM, MCL1 | ABL1 1958/4885BCR 2337/4885KIT 35/4885 |
| US-10391168-B1 | Anti-CD70 combination therapy | ABL1, BCR, CD2BP2 | ABL1 1/4885BCR 2/4885KIT 398/4885 |
| US-20130060030-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE CRYSTALLINE IMATINIB BASE | ABL1, ABL2, FGFR1 | ABL1 1/4885BCR 51/4885KIT 11/4885 |
| US-20210040454-A1 | Improved Differentiation Method | MYADM, EPCAM, KRT18 | ABL1 2107/4885BCR 2827/4885KIT 39/4885 |
| US-20170000789-A1 | Methods of Treating Tumoral Diseases, or Bacterial or Viral Infections | POLI, RNASE1, VHL | ABL1 351/4885BCR 1670/4885KIT 4083/4885 |
| US-20210047618-A1 | Improved Differentiation Method | VIPR2, IAPP, PROX1 | ABL1 3358/4885BCR 4482/4885KIT 49/4885 |
| US-11571475-B1 | Anti-CD70 and BCR-ABL inhibitor combination therapy | ABL1, BCR, ZAP70 | ABL1 1/4885BCR 2/4885KIT 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.